The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index; 83 of the 118 sources its claims cite were checked for support.
Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics
Open accessAbstract
Liver macrophages are master regulators of disease progression and resolution, whose functions transcend the simplistic M1/M2 dichotomy. This review synthesizes cutting-edge evidence to establish a dynamic, subset-centric paradigm for understanding macrophage plasticity. In acute liver injury, we delineate how temporally segregated subsets (e.g., early CCR2 + vs. late MerTK + macrophages) sequentially orchestrate damage and repair. In chronic settings—including HBV infection, MASLD/MASH, and fibrosis/cirrhosis—we reveal a complex coexistence of functionally opposed subsets that concurrently drive pathology (e.g., CD9 + TREM2 + macrophages) and promote resolution (e.g., CD300E + macrophages). This refined understanding underpins a critical appraisal of the evolving therapeutic landscape, which is pivoting from broad immunosuppression towards precision strategies. These include pharmacological targeting of specific recruitment or signaling pathways, adoptive transfer of reparative subsets, and innovative engineered cell therapies (e.g., signal-converting CAR-Ms). By framing macrophage functional duality within the “friend or foe” paradigm, this review provides a conceptual framework for developing subset-specific therapies that harness the beneficial while mitigating the harmful faces of hepatic macrophages. We highlight that the key translational challenge lies in mastering macrophage heterogeneity—requiring resolution of in vivo dynamics, cross-species discrepancies, and achievement of durable, context-specific modulation. The future of “macrophage medicine” hinges on integrating spatial multi-omics and advanced imaging to enable spatiotemporally precise interventions, ultimately leveraging the cell’s inherent plasticity for therapeutic gain.
Overview
CoChat Summary
TL;DR
This is a narrative review arguing that liver macrophages cannot be understood with a simple M1/M2 framework and instead should be viewed as dynamic, subset-specific actors that can either worsen or resolve liver disease. It also reviews a shift in therapy from broad immunosuppression to precision approaches such as subset-targeted drugs, adoptive transfer, and engineered macrophages.
Key findings
- In acute liver injury, macrophage functions change over time: early CCR2+ monocyte-derived macrophages drive damage, while later reparative subsets such as MerTK+ macrophages, CXCR4+ macrophages, TREM2+ LAMs, and MARCO+ macrophages support resolution and repair.
- In chronic liver disease, distinct subsets can simultaneously promote pathology and protection: examples include pro-inflammatory CD205+ macrophages in HBV, S100A4+ MoMFs and CD11chiMinclehi hLAMs in MASLD/MASH, and CD9+TREM2+ macrophages in fibrosis, alongside protective subsets such as OPN+ macrophages, CD209a-expressing macrophages, and CD300E+ MoMFs.
- Therapeutic translation is mixed: Cenicriviroc failed in the AURORA phase III trial to significantly alleviate fibrosis in NASH, while combination approaches and cell-based strategies show stronger promise in preclinical work.
- Clinical cell therapy evidence is early but encouraging: a phase I trial of autologous monocyte-derived macrophage reinfusion in cirrhosis was safe and was associated with improved MELD score and liver stiffness, but a later phase II randomized trial did not meet its primary endpoint at 90 days.
Methods
- Narrative review/synthesis of published studies on liver macrophage biology and therapy across acute injury, HBV, MASLD/MASH, and fibrosis/cirrhosis.
- Integrates evidence from experimental models, human patient studies, single-cell and single-nucleus RNA sequencing studies, and clinical trials.
- Main analytic approach is conceptual and comparative: it organizes macrophage subsets by disease context, timing, function, and therapeutic implications rather than performing a new quantitative meta-analysis.
Limitations
- The paper states that key translational challenges remain: unresolved in vivo subset dynamics, cross-species discrepancies, and difficulty achieving durable, context-specific modulation.
- It also notes gaps in knowledge about spatiotemporal relationships, lineage relationships, and the master regulators of phenotypic switching.
- Evident from the text: this is a review, so it does not present new primary data or a systematic quantitative synthesis of effect sizes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
69 Valid · 1 Not valid · 27 Not checked · 29 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“liver macrophages have emerged as key regulators of liver homeostasis and disease (6, 7).”
- Also stated in: § Introduction · plain
“As central sentinels and effectors of the hepatic innate immune system, liver macrophages have emerged as key regulators of liver homeostasis and disease (6, 7).”
§ Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics > Introduction
What the sources say
- Supportedcites [6] Guilliams, 2022, Liver macrophages in health and disease, Immunity source
The Abstract describes the involvement of liver macrophages in liver homeostasis and disease and their functional specialisations in both health and disease. This supports the citing sentence’s broad characterization of them as key regulators. (LLM, conf=0.91)
- Supportedcites [7] Guillot, 2024, Liver macrophages revisited: The expanding universe of versatile responses in a spatiotemporal context, Hepatol Commun source
The Introduction describes Kupffer cells as supporting liver blood filtering and immune tolerance during homeostasis. It also describes monocyte-derived macrophages as contributors to inflammation, fibrosis, and tissue repair in liver disease. Together, these passages support the broad claim. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“While the traditional M1/M2 polarization framework has been invaluable for conceptualizing macrophage functional duality, it is increasingly recognized as an oversimplification that fails to capture the full spectrum of phenotypes observed in vivo.”
§ Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics > Introduction
What the sources say
- Supportedcites [12] Kumar Jha, 2024, Macrophage heterogeneity and efferocytosis: Beyond the M1/M2 dichotomy, Circ Res source
The paper’s opening discussion says the M1/M2 dichotomy oversimplifies macrophage heterogeneity because the spectrum of subpopulations is wide. It also describes distinct macrophage clusters in human atherosclerotic plaques with greater functional heterogeneity than the classical M1/M2 model. (LLM, conf=0.94)
- Supportedcites [13] Lu, 2025, Beyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation, Redox Biol source
The “Limitations of the classic M1/M2 polarization model” section calls the dichotomy insufficient and describes distinct and hybrid macrophage phenotypes in fibrotic livers. Table 2 explicitly says the model is oversimplified and fails to capture in-vivo heterogeneity. The supplied passages do not specify page numbers. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Activated by IFN-γ, these cells secrete CCL12 to recruit additional CCR2+ monocytes, establishing a feed-forward loop of inflammation (40).”
§ Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics > Dynamic macrophage transitions in acute liver injury and repair: temporal functional evolution from pro-inflammatory to reparative > Pro-inflammatory macrophage subsets in the early injury phase
What the sources say
- Supportedcites [40] Lin, 2025, Bone marrow-derived CD169+ macrophages promote autoimmune hepatitis by recruiting CCR2+ monocytes via secreting CCL12, Exp Mol Med source
The Discussion describes IFNγ-responsive CD169+ macrophages as an amplifier that secretes CCL12, recruits more CCR2+ monocytes and macrophages, and aggravates acute liver injury. The Results sections on CCL12 expression and recruitment support the IFNγ response and monocyte recruitment in the ConA-induced AIH model. The copy provides no page numbers for these passages. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, IL-4 and IL-13 promote an alternatively activated (M2) phenotype, characterized by the secretion of IL-10 and TGF-β, which facilitate inflammation resolution and tissue repair (21, 22).”
§ Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics > Biological basis of liver macrophages: origin, heterogeneity, and plasticity
What the sources say
- Partly supportedcites [21] Feng, 2023, Monocyte-derived macrophages orchestrate multiple cell-type interactions to repair necrotic liver lesions in disease models, J Clin Invest sourceExperimental — accuracy not yet measured
The Introduction and Discussion (pages unavailable) describe macrophages helping resolve necrotic liver lesions and repair tissue. They do not establish that IL-4 and IL-13 promote an M2 phenotype, or that IL-10 and TGF-β secretion mediates that repair; searches for those terms found no supporting passage. (LLM, conf=0.86)
- Supportedcites [22] Tang, 2025, Novel regulators of hepatic macrophages in liver fibrosis, Front Immunol source
The “Hepatic macrophages” section states that IL-4 and IL-13 activate M2 macrophages and that M2 macrophages secrete IL-10 and TGF-β in support of immunosuppression and tissue repair. This supports the attributed paraphrase. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This is particularly evident in the liver, where single-cell technologies have revealed a far more intricate landscape of coexisting, specialized subsets beyond this binary classification (12, 13).”
§ Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics > Introduction
What the sources say
- Partly supportedcites [12] Kumar Jha, 2024, Macrophage heterogeneity and efferocytosis: Beyond the M1/M2 dichotomy, Circ Res sourceExperimental — accuracy not yet measured
The main text (page not provided) says single-cell technologies have revealed macrophage heterogeneity beyond the M1/M2 dichotomy. Its examples concern human atherosclerotic plaques and activated primary human macrophages, not the liver; the liver-specific part of the claim is unsupported by this source. (LLM, conf=0.86)
- Supportedcites [13] Lu, 2025, Beyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation, Redox Biol source
The ‘Limitations of the classic M1/M2 polarization model’ section says single-cell RNA sequencing identified more than ten macrophage clusters in fibrotic livers and describes the binary model as insufficient. Its Fig. 4 caption also identifies specialized subsets revealed by single-cell and spatial omics. The provided passages do not specify page numbers. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
57 more claims · 31 with their cited sources checked
Create a free account to see all 126 claims and to verify the 14 references still open.
- It may state two separate claims as one. 58
- Probably not a substantial claim. 8
- The quote only partly states this claim. 1
Citations
Cites
Global burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Bone marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells
Scott, C. L., Zheng, F., De Baetselier, P., Martens, L., Saeys, Y., De Prijck, S., Lippens, S., Abels, C., Schoonooghe, S., Raes, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms10321 · Cited by 860
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Yurdagul, A., Subramanian, M., Wang, X., Crown, S. B., Ilkayeva, O. R., Darville, L., Kolluru, G. K., Rymond, C. C., Gerlach, B. D., Zheng, Z., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.001 · Cited by 525
Establishment and Maintenance of the Macrophage Niche
Guilliams, M., Thierry, G. R., Bonnardel, J., & Bajenoff, M. (2020) · Immunity · doi:10.1016/j.immuni.2020.02.015 · Cited by 512
Metabolism of tissue macrophages in homeostasis and pathology
Wculek, S. K., Dunphy, G., Heras-Murillo, I., Mastrangelo, A., & Sancho, D. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00791-9 · Cited by 501
Blériot, C., Dupuis, T., Jouvion, G., Eberl, G., Disson, O., & Lecuit, M. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.020 · Cited by 471
Liver macrophages in health and disease
Guilliams, M., & Scott, C. L. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.002 · Cited by 395
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Efferocytosis induces macrophage proliferation to help resolve tissue injury
Gerlach, B. D., Ampomah, P. B., Yurdagul, A., Liu, C., Lauring, M. C., Wang, X., Kasikara, C., Kong, N., Shi, J., Tao, W., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.10.015 · Cited by 360
Cited by
Spatial immune niche remodeling of the neutrophil-macrophage axis inchronic liver disease
Ding, J., Xiong, X., Zhang, C., Fang, H., & Li, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1902627
Metadata
- Authors
- Chen, L., Chen, Y., Zhao, M., Yang, X., Sutte, K., Lu, M., Chen, J., Zheng, X., Yang, D., & Liu, J.
- Affiliations
- Wuhan Union Hospital (CN)
- Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Essen University Hospital (DE)
- Shanghai Medical College of Fudan University (CN)
- Corresponding author
- Liu, Jia
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2026-04-14
- Volume
- 17
- Pages
- 1814879-1814879
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC13120964
- OpenAlex
- W7154260907
- Cited by
- 1
- References
- 81
- Citations by year
- 2026: 1
- FWCI
- 1.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Key Research and Development Program of China (2023YFC2308502)
- National Natural Science Foundation of China (82172256, 92169105, M-0060, 82202037)
- Natural Science Foundation of Hubei Province (2025AFD795)
- National Mega Project on Major Infectious Disease Prevention (2026ZD01912302)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- hepatic macrophages, macrophage plasticity, CCR2+ macrophages, acute liver injury, chronic liver disease, hepatitis B virus, liver fibrosis, liver cirrhosis, adoptive macrophage transfer, macrophage recruitment, spatial multi-omics, liver regeneration
- MeSH terms
- Cell Plasticity, Animals, Humans, Liver Diseases, Macrophages, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics. https://app.cochat.ai/papers/10.3389/fimmu.2026.1814879
- The paper
- Chen, L., Chen, Y., Zhao, M., Yang, X., Sutte, K., Lu, M., Chen, J., Zheng, X., Yang, D., & Liu, J. (2026). Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1814879
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.